Project: Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes
Public Report Complete

Project Summary

Title and Description

Title

Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes

Comments (
0
) |
Post/View

Description

Technical brief for AHRQ on the evidence for whether PGHD devices and apps improve health outcomes for chronic conditions

Comments (
0
) |
Post/View

Contributor(s)

Jonathan R. Treadwell, Ph.D., James T. Reston Ph.D., Benjamin Rouse, M.H.S., Joann Fontanarosa, Ph.D., Neha Patel, M.D., Nikhil K Mull, M.D.

Comments (
0
) |
Post/View

DOI

Comments (
0
) |
Post/View

Funding Source

AHRQ

Comments (
0
) |
Post/View

Notes

Data and tables are at https://srdr.s3.amazonaws.com/uploads/12-07-2020/Appendixes+Technical+Brief+38+for+SRDR+12-7-20.docx

Comments (
0
) |
Post/View

Key Questions

Diabetes Prevention Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Diabetes Prevention Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Diabetes Prevention Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Diabetes Prevention Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Diabetes Prevention Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Obesity Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Obesity Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Obesity Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Obesity Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Obesity Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Sleep Apnea Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Sleep Apnea Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Sleep Apnea Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Sleep Apnea Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Sleep Apnea Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Hypertension Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Hypertension Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Hypertension Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Hypertension Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Hypertension Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Coronary Artery Disease Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Coronary Artery Disease Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Coronary Artery Disease Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Coronary Artery Disease Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Coronary Artery Disease Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Heart Failure Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Heart Failure Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Heart Failure Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Heart Failure Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Heart Failure Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Cardiac Arrhythmias Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Cardiac Arrhythmias Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Cardiac Arrhythmias Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Cardiac Arrhythmias Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Cardiac Arrhythmias Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Asthma Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Asthma Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Asthma Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Asthma Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Asthma Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Stroke Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

Stroke Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

Stroke Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

Stroke Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

Stroke Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

COPD Guiding Question 1. Which specific consumer automated-entry PGHD applications/technologies/devices have been studied for measurement of health outcomes? What studies are in progress of consumer PGHD devices?

Comments (
0
) |
Post/View

COPD Guiding Question 2. What are the characteristics (e.g., interoperability, functions, acceptability/usability, sustainability, feasibility, fidelity, or integration into electronic health records) of these specific consumer automated-entry PGHD technologies?

Comments (
0
) |
Post/View

COPD Guiding Question 3. What is the influence of specific consumer automated-entry PGHD technologies on health outcomes? Does this vary across different patient populations, different settings, or other modifiers of effectiveness?

Comments (
0
) |
Post/View

COPD Guiding Question 4. What are the harms or adverse events associated with these specific consumer automated-entry PGHD technologies? Which patients in which settings are most at risk of harms?

Comments (
0
) |
Post/View

COPD Guiding Question 5. For the technologies demonstrating associations with outcomes of interest, what full economic evaluations provide information on the relative value for consumers?

Comments (
0
) |
Post/View

Associated Extraction Forms

Title	Created by	Key Questions Addressed
Diabetes prevention	Jonathan Treadwell	1, 2, 3, 4, 5
Obesity	Jacki Hostetter	6, 7, 8, 9, 10
Sleep Apnea	Jacki Hostetter	11, 12, 13, 14, 15
Hypertension	Jacki Hostetter	16, 17, 18, 19, 20
Coronary Artery Disease	Jacki Hostetter	21, 22, 23, 24, 25
Heart Failure	Jacki Hostetter	26, 27, 28, 29, 30
Cardiac Arrhythmias	Jacki Hostetter	31, 32, 33, 34, 35
Asthma	Jacki Hostetter	36, 37, 38, 39, 40
Stroke	Jacki Hostetter	41, 42, 43, 44, 45
COPD	Jacki Hostetter	46, 47, 48, 49, 50

Associated Studies (each link opens a new tab)

Title	Author	Year
A Randomised Controlled Trial to Reduce Sedentary Time in Young Adults at Risk of Type 2 Diabetes Mellitus: Project STAND (Sedentary Time ANd Diabetes).	Biddle SJ., Edwardson CL., Wilmot EG., Yates T., Gorely T., Bodicoat DH., Ashra N., Khunti K., Nimmo MA., Davies MJ.	2015
Mobile health, exercise and metabolic risk: a randomized controlled trial.	Petrella RJ., Stuckey MI., Shapiro S., Gill DP.	2014
Comparative effectiveness of guided weight loss and physical activity monitoring for weight loss and metabolic risks: A pilot study.	Peyer KL., Ellingson LD., Bus K., Walsh SA., Franke WD., Welk GJ.	2017
A Randomised Controlled Trial to Reduce Sedentary Time in Young Adults at Risk of Type 2 Diabetes Mellitus: Project STAND (Sedentary Time ANd Diabetes).	Biddle SJ., Edwardson CL., Wilmot EG., Yates T., Gorely T., Bodicoat DH., Ashra N., Khunti K., Nimmo MA., Davies MJ.	2015
Comparative effectiveness of guided weight loss and physical activity monitoring for weight loss and metabolic risks: A pilot study.	Peyer KL., Ellingson LD., Bus K., Walsh SA., Franke WD., Welk GJ.	2017
Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: The IDEA Randomized Clinical Trial.	Jakicic JM., Davis KK., Rogers RJ., King WC., Marcus MD., Helsel D., Rickman AD., Wahed AS., Belle SH.	2016
Impact of newer self-monitoring technology and brief phone-based intervention on weight loss: A randomized pilot study.	Ross KM., Wing RR.	2016
A randomized trial comparing two interventions to increase physical activity among patients undergoing bariatric surgery.	Creel DB., Schuh LM., Reed CA., Gomez AR., Hurst LA., Stote J., Cacucci BM.	2016
Self-monitoring of spontaneous physical activity and sedentary behavior to prevent weight regain in older adults.	Nicklas BJ., Gaukstern JE., Beavers KM., Newman JC., Leng X., Rejeski WJ.	2014
Text4Diet: a randomized controlled study using text messaging for weight loss behaviors.	Shapiro JR., Koro T., Doran N., Thompson S., Sallis JF., Calfas K., Patrick K.	2012
A short-term physical activity randomized trial in the Lower Mississippi Delta.	Katzmarzyk PT., Champagne CM., Tudor-Locke C., Broyles ST., Harsha D., Kennedy BM., Johnson WD.	2011
Electronic feedback in a diet- and physical activity-based lifestyle intervention for weight loss: a randomized controlled trial.	Shuger SL., Barry VW., Sui X., McClain A., Hand GA., Wilcox S., Meriwether RA., Hardin JW., Blair SN.	2011
The Effectiveness of Mobile Phone-Based Care for Weight Control in Metabolic Syndrome Patients: Randomized Controlled Trial.	Oh B., Cho B., Han MK., Choi H., Lee MN., Kang HC., Lee CH., Yun H., Kim Y.	2015
A pragmatic randomised controlled trial in primary care of the Camden Weight Loss (CAMWEL) programme.	Nanchahal K., Power T., Holdsworth E., Hession M., Sorhaindo A., Griffiths U., Townsend J., Thorogood N., Haslam D., Kessel A., Ebrahim S., Kenward M., Haines A.	2012
CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.	Mendelson M., Vivodtzev I., Tamisier R., Laplaud D., Dias-Domingos S., Baguet JP., Moreau L., Koltes C., Chavez L., De Lamberterie G., Herengt F., Levy P., Flore P., Pépin JL.	2014
Effectiveness of an App and Provider Counseling for Obesity Treatment in Primary Care.	Bennett GG., Steinberg D., Askew S., Levine E., Foley P., Batch BC., Svetkey LP., Bosworth HB., Puleo EM., Brewer A., DeVries A., Miranda H.	2018
e-Care for heart wellness: a feasibility trial to decrease blood pressure and cardiovascular risk.	Green BB., Anderson ML., Cook AJ., Catz S., Fishman PA., McClure JB., Reid RJ.	2014
DASH to wellness: emphasizing self-regulation through e-health in adults with prehypertension.	Dorough AE., Winett RA., Anderson ES., Davy BM., Martin EC., Hedrick V.	2014
Efficacy of SmartLoss, a smartphone-based weight loss intervention: results from a randomized controlled trial.	Martin CK., Miller AC., Thomas DM., Champagne CM., Han H., Church T.	2015
Web-based intervention to promote weight-loss maintenance using an activity monitor: A randomized controlled trial.	Nakata Y., Sasai H., Tsujimoto T., Hashimoto K., Kobayashi H.	2019
Impact of Personal Health Records and Wearables on Health Outcomes and Patient Response: Three-Arm Randomized Controlled Trial.	Kim JW., Ryu B., Cho S., Heo E., Kim Y., Lee J., Jung SY., Yoo S.	2019
Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial.	Ferrante JM., Devine KA., Bator A., Rodgers A., Ohman-Strickland PA., Bandera EV., Hwang KO.	2018
Multicomponent intervention to reduce daily sedentary time: a randomised controlled trial.	Carr LJ., Karvinen K., Peavler M., Smith R., Cangelosi K.	2013
A Technology-Mediated Behavioral Weight Gain Prevention Intervention for College Students: Controlled, Quasi-Experimental Study.	West DS., Monroe CM., Turner-McGrievy G., Sundstrom B., Larsen C., Magradey K., Wilcox S., Brandt HM.	2016
Applying a technology-based system for weight loss in adults with obesity.	Rogers RJ., Lang W., Barone Gibbs B., Davis KK., Burke LE., Kovacs SJ., Portzer LA., Jakicic JM.	2016
A Randomized, Controlled, Multicenter Study of Technology-Based Weight Loss Interventions among Endometrial Cancer Survivors.	Haggerty AF., Hagemann A., Barnett M., Thornquist M., Neuhouser ML., Horowitz N., Colditz GA., Sarwer DB., Ko EM., Allison KC.	2017
The Effect of Different Types of Monitoring Strategies on Weight Loss: A Randomized Controlled Trial.	Jospe MR., Roy M., Brown RC., Williams SM., Osborne HR., Meredith-Jones KA., McArthur JR., Fleming EA., Taylor RW.	2017
The Dietary Intervention to Enhance Tracking with Mobile Devices (DIET Mobile) Study: A 6-Month Randomized Weight Loss Trial.	Turner-McGrievy GM., Wilcox S., Boutté A., Hutto BE., Singletary C., Muth ER., Hoover AW.	2017
Effects of an abbreviated obesity intervention supported by mobile technology: The ENGAGED randomized clinical trial.	Spring B., Pellegrini CA., Pfammatter A., Duncan JM., Pictor A., McFadden HG., Siddique J., Hedeker D.	2017
Weight loss in Weight Watchers Online with and without an activity tracking device compared to control: A randomized trial.	Thomas JG., Raynor HA., Bond DS., Luke AK., Cardoso CC., Foster GD., Wing RR.	2017
Enhancing physical activity and reducing obesity through smartcare and financial incentives: A pilot randomized trial.	Shin DW., Yun JM., Shin JH., Kwon H., Min HY., Joh HK., Chung WJ., Park JH., Jung KT., Cho B.	2017
A Randomized Study of Exercise and Fitness Trackers in Obese Patients After Total Knee Arthroplasty.	Smith WA., Zucker-Levin A., Mihalko WM., Williams M., Loftin M., Gurney JG.	2019
Long-term efficacy and effectiveness of a behavioural and community-based exercise intervention (Urban Training) to increase physical activity in patients with COPD: a randomised controlled trial.	Arbillaga-Etxarri A., Gimeno-Santos E., Barberan-Garcia A., Balcells E., Benet M., Borrell E., Celorrio N., Delgado A., Jané C., Marin A., Martín-Cantera C., Monteagudo M., Montellà N., Muñoz L., Ortega P., Rodríguez DA., Rodríguez-Roisin R., Simonet P., Torán-Monserrat P., Torrent-Pallicer J., Vall-Casas P., Vilaró J., Garcia-Aymerich J.	2018
Efficacy of an mHealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation.	Vorrink SN., Kort HS., Troosters T., Zanen P., Lammers JJ.	2016
Combined use of a wristband and a smartphone to reduce body weight in obese children: randomized controlled trial.	Mameli C., Brunetti D., Colombo V., Bedogni G., Schneider L., Penagini F., Borsani B., Zuccotti GV.	2018
Randomized Trial of a Fitbit-Based Physical Activity Intervention for Women.	Cadmus-Bertram LA., Marcus BH., Patterson RE., Parker BA., Morey BL.	2015
Telephone counseling and home telemonitoring: the Weigh by Day Trial.	VanWormer JJ., Martinez AM., Benson GA., Crain AL., Martinson BC., Cosentino DL., Pronk NP.	-- Not Found --
The efficacy of a technology-based system in a short-term behavioral weight loss intervention.	Polzien KM., Jakicic JM., Tate DF., Otto AD.	2007
Effectiveness of home-centered care through telemedicine applications for overweight and obese patients: a randomized controlled trial.	Goulis DG., Giaglis GD., Boren SA., Lekka I., Bontis E., Balas EA., Maglaveras N., Avramides A.	2004
A Ubiquitous Chronic Disease Care system using cellular phones and the internet.	Yoo HJ., Park MS., Kim TN., Yang SJ., Cho GJ., Hwang TG., Baik SH., Choi DS., Park GH., Choi KM.	2009
Effect of Lifestyle Modification Using a Smartphone Application on Obesity With Obstructive Sleep Apnea: A Short-term, Randomized Controlled Study.	Cho SW., Wee JH., Yoo S., Heo E., Ryu B., Kim Y., Lee JS., Kim JW.	2018
Short-Term Efficacy of an Innovative Mobile Phone Technology-Based Intervention for Weight Management for Overweight and Obese Adolescents: Pilot Study.	Chen JL., Guedes CM., Cooper BA., Lung AE.	2017
A Comparative Effectiveness Trial of Three Walking Self-monitoring Strategies.	Richardson CR., Goodrich DE., Larkin AR., Ronis D., Holleman RG., Damschroder LJ., Lowery JC.	2016
Effectiveness of Facebook-Delivered Lifestyle Counselling and Physical Activity Self-Monitoring on Physical Activity and Body Mass Index in Overweight and Obese Adolescents: A Randomized Controlled Trial.	Ruotsalainen H., Kyngäs H., Tammelin T., Heikkinen H., Kääriäinen M.	2015
Short- and Long-term Effects of a Mobile Phone App in Conjunction With Brief In-Person Counseling on Physical Activity Among Physically Inactive Women: The mPED Randomized Clinical Trial.	Fukuoka Y., Haskell W., Lin F., Vittinghoff E.	2019
A Social Networking and Gamified App to Increase Physical Activity: Cluster RCT.	Edney SM., Olds TS., Ryan JC., Vandelanotte C., Plotnikoff RC., Curtis RG., Maher CA.	2020
CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.	Mendelson M., Vivodtzev I., Tamisier R., Laplaud D., Dias-Domingos S., Baguet JP., Moreau L., Koltes C., Chavez L., De Lamberterie G., Herengt F., Levy P., Flore P., Pépin JL.	2014
Impact of Personal Health Records and Wearables on Health Outcomes and Patient Response: Three-Arm Randomized Controlled Trial.	Kim JW., Ryu B., Cho S., Heo E., Kim Y., Lee J., Jung SY., Yoo S.	2019
Effect of Lifestyle Modification Using a Smartphone Application on Obesity With Obstructive Sleep Apnea: A Short-term, Randomized Controlled Study.	Cho SW., Wee JH., Yoo S., Heo E., Ryu B., Kim Y., Lee JS., Kim JW.	2018
CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.	Mendelson M., Vivodtzev I., Tamisier R., Laplaud D., Dias-Domingos S., Baguet JP., Moreau L., Koltes C., Chavez L., De Lamberterie G., Herengt F., Levy P., Flore P., Pépin JL.	2014
Effectiveness of an App and Provider Counseling for Obesity Treatment in Primary Care.	Bennett GG., Steinberg D., Askew S., Levine E., Foley P., Batch BC., Svetkey LP., Bosworth HB., Puleo EM., Brewer A., DeVries A., Miranda H.	2018
e-Care for heart wellness: a feasibility trial to decrease blood pressure and cardiovascular risk.	Green BB., Anderson ML., Cook AJ., Catz S., Fishman PA., McClure JB., Reid RJ.	2014
DASH to wellness: emphasizing self-regulation through e-health in adults with prehypertension.	Dorough AE., Winett RA., Anderson ES., Davy BM., Martin EC., Hedrick V.	2014
A Ubiquitous Chronic Disease Care system using cellular phones and the internet.	Yoo HJ., Park MS., Kim TN., Yang SJ., Cho GJ., Hwang TG., Baik SH., Choi DS., Park GH., Choi KM.	2009
Mobile health, exercise and metabolic risk: a randomized controlled trial.	Petrella RJ., Stuckey MI., Shapiro S., Gill DP.	2014
Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study.	Márquez-Contreras E., Martell-Claros N., Gil-Guillén V., de la Figuera-Von Wichmann M., Casado-Martínez JJ., Martin-de Pablos JL., Figueras M., Galera J., Serra A.	2006
Improving blood pressure control in hypertensive hemodialysis patients.	Kauric-Klein Z., Artinian N.	-- Not Found --
A mHealth-based care model for improving hypertension control in stroke survivors: Pilot RCT.	Lakshminarayan K., Westberg S., Northuis C., Fuller CC., Ikramuddin F., Ezzeddine M., Scherber J., Speedie S.	2018
Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial.	McManus RJ., Mant J., Haque MS., Bray EP., Bryan S., Greenfield SM., Jones MI., Jowett S., Little P., Penaloza C., Schwartz C., Shackleford H., Shovelton C., Varghese J., Williams B., Hobbs FD., Gooding T., Morrey I., Fisher C., Buckley D.	2014
Short-term telemedical home blood pressure monitoring does not improve blood pressure in uncomplicated hypertensive patients.	Hoffmann-Petersen N., Lauritzen T., Bech JN., Pedersen EB.	2017
The Influence of Wireless Self-Monitoring Program on the Relationship Between Patient Activation and Health Behaviors, Medication Adherence, and Blood Pressure Levels in Hypertensive Patients: A Substudy of a Randomized Controlled Trial.	Kim JY., Wineinger NE., Steinhubl SR.	2016
Self-monitoring of blood pressure for improving adherence to antihypertensive medicines and blood pressure control: a randomized controlled trial.	Hosseininasab M., Jahangard-Rafsanjani Z., Mohagheghi A., Sarayani A., Rashidian A., Javadi M., Ahmadvand A., Hadjibabaie M., Gholami K.	2014
Counseling African Americans to Control Hypertension: cluster-randomized clinical trial main effects.	Ogedegbe G., Tobin JN., Fernandez S., Cassells A., Diaz-Gloster M., Khalida C., Pickering T., Schwartz JE.	2014
Home based telemedicine intervention for patients with uncontrolled hypertension--a real life non-randomized study.	Bernocchi P., Scalvini S., Bertacchini F., Rivadossi F., Muiesan ML.	2014
A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial).	Stewart K., George J., Mc Namara KP., Jackson SL., Peterson GM., Bereznicki LR., Gee PR., Hughes JD., Bailey MJ., Hsueh YA., McDowell JM., Bortoletto DA., Lau R.	2014
Lack of impact of a comprehensive intervention on hypertension in the primary care setting.	Niiranen TJ., Leino K., Puukka P., Kantola I., Karanko H., Jula AM.	2014
Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.	McManus RJ., Mant J., Franssen M., Nickless A., Schwartz C., Hodgkinson J., Bradburn P., Farmer A., Grant S., Greenfield SM., Heneghan C., Jowett S., Martin U., Milner S., Monahan M., Mort S., Ogburn E., Perera-Salazar R., Shah SA., Yu LM., Tarassenko L., Hobbs FDR.	2018
Home BP monitoring using a telemonitoring system is effective for controlling BP in a remote island in Japan.	Kaihara T., Eguchi K., Kario K.	2014
Randomized clinical trial to assess the effectiveness of remote patient monitoring and physician care in reducing office blood pressure.	Kim YN., Shin DG., Park S., Lee CH.	2015
Effect of a Community Health Worker-Led Multicomponent Intervention on Blood Pressure Control in Low-Income Patients in Argentina: A Randomized Clinical Trial.	He J., Irazola V., Mills KT., Poggio R., Beratarrechea A., Dolan J., Chen CS., Gibbons L., Krousel-Wood M., Bazzano LA., Nejamis A., Gulayin P., Santero M., Augustovski F., Chen J., Rubinstein A.	2017
Phone-based intervention for blood pressure control among Ghanaian stroke survivors: A pilot randomized controlled trial.	Sarfo FS., Treiber F., Gebregziabher M., Adamu S., Nichols M., Singh A., Obese V., Sarfo-Kantanka O., Sakyi A., Adu-Darko N., Tagge R., Agyei-Frimpong M., Kwarteng N., Badu E., Mensah N., Ampofo M., Jenkins C., Ovbiagele B.	2019
Intensive versus conventional blood pressure monitoring in a general practice population. The Blood Pressure Reduction in Danish General Practice trial: a randomized controlled parallel group trial.	Klarskov P., Bang LE., Schultz-Larsen P., Gregers Petersen H., Benee Olsen D., Berg RMG., Abrahamsen H., Wiinberg N.	2018
Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke: a community-based randomized controlled trial.	Kerry SM., Markus HS., Khong TK., Cloud GC., Tulloch J., Coster D., Ibison J., Oakeshott P.	2013
Using the immediate blood pressure benefits of exercise to improve exercise adherence among adults with hypertension: a randomized clinical trial.	Zaleski AL., Taylor BA., Park CL., Santos LP., Panza G., Kramarz M., McCormick K., Thompson PD., Fernandez AB., Chen MH., Blissmer B., Gans KM., Pescatello LS.	2019
Effectiveness of Self-Monitoring Blood Pressure in Primary Care: A Randomized Controlled Trial.	Aekplakorn W., Suriyawongpaisal P., Tansirisithikul R., Sakulpipat T., Charoensuk P.	2016
Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial.	Margolis KL., Asche SE., Bergdall AR., Dehmer SP., Groen SE., Kadrmas HM., Kerby TJ., Klotzle KJ., Maciosek MV., Michels RD., O'Connor PJ., Pritchard RA., Sekenski JL., Sperl-Hillen JM., Trower NK.	2013
Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial.	McKinstry B., Hanley J., Wild S., Pagliari C., Paterson M., Lewis S., Sheikh A., Krishan A., Stoddart A., Padfield P.	2013
Managing hypertension in urban underserved subjects using telemedicine--a clinical trial.	Bove AA., Homko CJ., Santamore WP., Kashem M., Kerper M., Elliott DJ.	2013
A pharmacist-led, American Heart Association Heart360 Web-enabled home blood pressure monitoring program.	Magid DJ., Olson KL., Billups SJ., Wagner NM., Lyons EE., Kroner BA.	2013
Linking clinic and home: a randomized, controlled clinical effectiveness trial of real-time, wireless blood pressure monitoring for older patients with kidney disease and hypertension.	Rifkin DE., Abdelmalek JA., Miracle CM., Low C., Barsotti R., Rios P., Stepnowsky C., Agha Z.	2013
Effect of home blood pressure telemonitoring with self-care support on uncontrolled systolic hypertension in diabetics.	Logan AG., Irvine MJ., McIsaac WJ., Tisler A., Rossos PG., Easty A., Feig DS., Cafazzo JA.	2012
Nurse-led disease management for hypertension control in a diverse urban community: a randomized trial.	Hebert PL., Sisk JE., Tuzzio L., Casabianca JM., Pogue VA., Wang JJ., Chen Y., Cowles C., McLaughlin MA.	2012
Efficacy of isolated home blood pressure monitoring for blood pressure control: randomized controlled trial with ambulatory blood pressure monitoring - MONITOR study.	Fuchs SC., Ferreira-da-Silva AL., Moreira LB., Neyeloff JL., Fuchs FC., Gus M., Wiehe M., Fuchs FD.	2012
Blood pressure telemonitoring is useful to achieve blood pressure control in inadequately treated patients with arterial hypertension.	Neumann CL., Menne J., Rieken EM., Fischer N., Weber MH., Haller H., Schulz EG.	2011
Home blood pressure management and improved blood pressure control: results from a randomized controlled trial.	Bosworth HB., Powers BJ., Olsen MK., McCant F., Grubber J., Smith V., Gentry PW., Rose C., Van Houtven C., Wang V., Goldstein MK., Oddone EZ.	2011
Racial differences in two self-management hypertension interventions.	Bosworth HB., Olsen MK., Grubber JM., Powers BJ., Oddone EZ.	2011
A multimodal blood pressure control intervention in 3 healthcare systems.	Magid DJ., Ho PM., Olson KL., Brand DW., Welch LK., Snow KE., Lambert-Kerzner AC., Plomondon ME., Havranek EP.	2011
Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial.	McManus RJ., Mant J., Bray EP., Holder R., Jones MI., Greenfield S., Kaambwa B., Banting M., Bryan S., Little P., Williams B., Hobbs FD.	2010
Mobile telemonitoring for achieving tighter targets of blood pressure control in patients with complicated diabetes: a pilot study.	Earle KA., Istepanian RS., Zitouni K., Sungoor A., Tang B.	2010
Two self-management interventions to improve hypertension control: a randomized trial.	Bosworth HB., Olsen MK., Grubber JM., Neary AM., Orr MM., Powers BJ., Adams MB., Svetkey LP., Reed SD., Li Y., Dolor RJ., Oddone EZ.	2009
Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial.	Green BB., Cook AJ., Ralston JD., Fishman PA., Catz SL., Carlson J., Carrell D., Tyll L., Larson EB., Thompson RS.	2008
Self-monitoring of blood pressure promotes achievement of blood pressure target in primary health care.	Halme L., Vesalainen R., Kaaja M., Kantola I.	2005
Management of hypertension in the elderly using home blood pressures.	Broege PA., James GD., Pickering TG.	2001
Home monitoring service improves mean arterial pressure in patients with essential hypertension. A randomized, controlled trial.	Rogers MA., Small D., Buchan DA., Butch CA., Stewart CM., Krenzer BE., Husovsky HL.	2001
Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension.	Mehos BM., Saseen JJ., MacLaughlin EJ.	2000
A randomized study comparing a patient-directed hypertension management strategy with usual office-based care.	Zarnke KB., Feagan BG., Mahon JL., Feldman RD.	1997
Utilizing a Mobile Health Intervention to Manage Hypertension in an Underserved Community.	Zha P., Qureshi R., Porter S., Chao YY., Pacquiao D., Chase S., O'Brien-Richardson P.	2020
A Web-Based Self-Titration Program to Control Blood Pressure in Patients With Primary Hypertension: Randomized Controlled Trial.	Kao CW., Chen TY., Cheng SM., Lin WS., Chang YC.	2019
Impact of 12-Month Smartphone Breathing Meditation Program upon Systolic Blood Pressure among Non-Medicated Stage 1 Hypertensive Adults.	Chandler J., Sox L., Diaz V., Kellam K., Neely A., Nemeth L., Treiber F.	2020
CPAP treatment supported by telemedicine does not improve blood pressure in high cardiovascular risk OSA patients: a randomized, controlled trial.	Mendelson M., Vivodtzev I., Tamisier R., Laplaud D., Dias-Domingos S., Baguet JP., Moreau L., Koltes C., Chavez L., De Lamberterie G., Herengt F., Levy P., Flore P., Pépin JL.	2014
Improving access to cardiac rehabilitation using the internet: a randomized trial.	Lear SA., Singer J., Banner-Lukaris D., Horvat D., Park JE., Bates J., Ignaszewski A.	2015
Home-Based Rehabilitation With Telemonitoring Guidance for Patients With Coronary Artery Disease (Short-Term Results of the TRiCH Study): Randomized Controlled Trial.	Avila A., Claes J., Goetschalckx K., Buys R., Azzawi M., Vanhees L., Cornelissen V.	2018
Increasing the medium-term clinical benefits of hospital-based cardiac rehabilitation by physical activity telemonitoring in coronary artery disease patients.	Frederix I., Van Driessche N., Hansen D., Berger J., Bonne K., Alders T., Dendale P.	2015
Evaluation of a telemedicine service for the secondary prevention of coronary artery disease.	Blasco A., Carmona M., Fernández-Lozano I., Salvador CH., Pascual M., Sagredo PG., Somolinos R., Muñoz A., García-López F., Escudier JM., Mingo S., Toquero J., Moñivas V., González MA., Fragua JA., López-Rodríguez F., Monteagudo JL., Alonso-Pulpón L.	-- Not Found --
Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: Results of the FIT@Home study.	Kraal JJ., Van den Akker-Van Marle ME., Abu-Hanna A., Stut W., Peek N., Kemps HM.	2017
Effect of Smartphone-Enabled Health Monitoring Devices vs Regular Follow-up on Blood Pressure Control Among Patients After Myocardial Infarction: A Randomized Clinical Trial.	Treskes RW., van Winden LAM., van Keulen N., van der Velde ET., Beeres SLMA., Atsma DE., Schalij MJ.	2020
Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial.	Ong MK., Romano PS., Edgington S., Aronow HU., Auerbach AD., Black JT., De Marco T., Escarce JJ., Evangelista LS., Hanna B., Ganiats TG., Greenberg BH., Greenfield S., Kaplan SH., Kimchi A., Liu H., Lombardo D., Mangione CM., Sadeghi B., Sadeghi B., Sarrafzadeh M., Tong K., Fonarow GC.	2016
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial.	Koehler F., Koehler K., Deckwart O., Prescher S., Wegscheider K., Kirwan BA., Winkler S., Vettorazzi E., Bruch L., Oeff M., Zugck C., Doerr G., Naegele H., Störk S., Butter C., Sechtem U., Angermann C., Gola G., Prondzinsky R., Edelmann F., Spethmann S., Schellong SM., Schulze PC., Bauersachs J., Wellge B., Schoebel C., Tajsic M., Dreger H., Anker SD., Stangl K.	2018
Mobile phone-based telemonitoring for heart failure management: a randomized controlled trial.	Seto E., Leonard KJ., Cafazzo JA., Barnsley J., Masino C., Ross HJ.	2012
Use of remote monitoring to improve outcomes in patients with heart failure: a pilot trial.	Kulshreshtha A., Kvedar JC., Goyal A., Halpern EF., Watson AJ.	2010
Effect of home-based telemonitoring using mobile phone technology on the outcome of heart failure patients after an episode of acute decompensation: randomized controlled trial.	Scherr D., Kastner P., Kollmann A., Hallas A., Auer J., Krappinger H., Schuchlenz H., Stark G., Grander W., Jakl G., Schreier G., Fruhwald FM.	2009
The impact of telehealth care on health-related quality of life of patients with heart failure: Results from the Danish TeleCare North heart failure trial.	Cichosz SL., Udsen FW., Hejlesen O.	-- Not Found --
Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study.	Halcox JPJ., Wareham K., Cardew A., Gilmore M., Barry JP., Phillips C., Gravenor MB.	2017
Intermittent vs. Continuous Anticoagulation theRapy in patiEnts with Atrial Fibrillation (iCARE-AF): a randomized pilot study.	Stavrakis S., Stoner JA., Kardokus J., Garabelli PJ., Po SS., Lazzara R.	2017
Multi-centre Randomised Controlled Trial of a Smartphone-based Event Recorder Alongside Standard Care Versus Standard Care for Patients Presenting to the Emergency Department with Palpitations and Pre-syncope: The IPED (Investigation of Palpitations in the ED) study.	Reed MJ., Grubb NR., Lang CC., O'Brien R., Simpson K., Padarenga M., Grant A., Tuck S., Keating L., Coffey F., Jones L., Harris T., Lloyd G., Gagg J., Smith JE., Coats T.	2019
Recurrent atrial fibrillation/flutter detection after ablation or cardioversion using the AliveCor KardiaMobile device: iHEART results.	Goldenthal IL., Sciacca RR., Riga T., Bakken S., Baumeister M., Biviano AB., Dizon JM., Wang D., Wang KC., Whang W., Hickey KT., Garan H.	2019
Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial.	Ljungberg H., Carleborg A., Gerber H., Öfverström C., Wolodarski J., Menshi F., Engdahl M., Eduards M., Nordlund B.	2019
Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke: a community-based randomized controlled trial.	Kerry SM., Markus HS., Khong TK., Cloud GC., Tulloch J., Coster D., Ibison J., Oakeshott P.	2013
Long-term efficacy and effectiveness of a behavioural and community-based exercise intervention (Urban Training) to increase physical activity in patients with COPD: a randomised controlled trial.	Arbillaga-Etxarri A., Gimeno-Santos E., Barberan-Garcia A., Balcells E., Benet M., Borrell E., Celorrio N., Delgado A., Jané C., Marin A., Martín-Cantera C., Monteagudo M., Montellà N., Muñoz L., Ortega P., Rodríguez DA., Rodríguez-Roisin R., Simonet P., Torán-Monserrat P., Torrent-Pallicer J., Vall-Casas P., Vilaró J., Garcia-Aymerich J.	2018
Efficacy of an mHealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation.	Vorrink SN., Kort HS., Troosters T., Zanen P., Lammers JJ.	2016
Tele-monitoring reduces exacerbation of COPD in the context of climate change--a randomized controlled trial.	Jehn M., Donaldson G., Kiran B., Liebers U., Mueller K., Scherer D., Endlicher W., Witt C.	2013
A telerehabilitation intervention for patients with Chronic Obstructive Pulmonary Disease: a randomized controlled pilot trial.	Tabak M., Vollenbroek-Hutten MM., van der Valk PD., van der Palen J., Hermens HJ.	2014
Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy.	Jódar-Sánchez F., Ortega F., Parra C., Gómez-Suárez C., Jordán A., Pérez P., Bonachela P., Leal S., Barrot E.	2013
Pedometer Step Count Targets during Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.	Nolan CM., Maddocks M., Canavan JL., Jones SE., Delogu V., Kaliaraju D., Banya W., Kon SSC., Polkey MI., Man WD.	2017
Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial.	Demeyer H., Louvaris Z., Frei A., Rabinovich RA., de Jong C., Gimeno-Santos E., Loeckx M., Buttery SC., Rubio N., Van der Molen T., Hopkinson NS., Vogiatzis I., Puhan MA., Garcia-Aymerich J., Polkey MI., Troosters T.	2017
Effects of low-intensity exercise and home-based pulmonary rehabilitation with pedometer feedback on physical activity in elderly patients with chronic obstructive pulmonary disease.	Kawagoshi A., Kiyokawa N., Sugawara K., Takahashi H., Sakata S., Satake M., Shioya T.	2015
A Smart Mobile Health Tool Versus a Paper Action Plan to Support Self-Management of Chronic Obstructive Pulmonary Disease Exacerbations: Randomized Controlled Trial.	Boer L., Bischoff E., van der Heijden M., Lucas P., Akkermans R., Vercoulen J., Heijdra Y., Assendelft W., Schermer T.	2019
Outpatient vs. home-based pulmonary rehabilitation in COPD: a randomized controlled trial.	Mendes de Oliveira JC., Studart Leitão Filho FS., Malosa Sampaio LM., Negrinho de Oliveira AC., Hirata RP., Costa D., Donner CF., de Oliveira LV.	2010

Creative Commons
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/

Select a Topic:
Your Feedback:

Project: Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes Public Report Complete

Project: Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes

Project Summary

Exit Disclaimer

Project: Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes
Public Report Complete